Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022.

Pharmacological management of airway obstructive diseases is a fast-evolving field. Several advances in unravelling disease mechanisms as well as intracellular and molecular pathways of drug action have been accomplished. While the clinical translation and implementation of in vitro results to the bedside remains challenging, advances in comprehending the mechanisms of respiratory medication are expected to assist clinicians and scientists in identifying meaningful read-outs and designing clinical studies. This European Respiratory Society Research Seminar, held in Naples, Italy, 5-6 May 2022, focused on current and future developments of the drugs used to treat asthma and COPD; on mechanisms of drug action, steroid resistance, comorbidities and drug interactions; on prognostic and therapeutic biomarkers; on developing novel drug targets based on tissue remodelling and regeneration; and on pharmacogenomics and emerging biosimilars. Related European Medicines Agency regulations are also discussed, as well as the seminar's position on the above aspects.
Competing Interests: Conflict of interest: The following authors declared that they have no significant relationships with manufacturer(s) of any commercial product(s) or provider(s) of any commercial service(s) discussed during their presentation in Naples and/or with the manuscript: L. Fregonese, A.G. Mathioudakis, E. Papakonstantinou and M. Rukhadze. The following authors have declared that they have real or perceived conflicts of interest with manufacturer(s) of any commercial product(s) or provider(s) of any commercial service(s) discussed during their presentation in Naples and/or in the manuscript. Company/institution names appear as provided by the authors in their ICMJE disclosure form. M. van den Berge: his institution has received grants or contracts from GlaxoSmithKline, Roche, Novartis, AstraZeneca and Sanofi. M. Cazzola: has personally received a) consulting fees from ABC Farmaceutici, Lallemand and Recipharm; b) payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Glenmark, Cipla, Sanofi, Chiesi Farmaceutici, Abdi Ibrahim, Mankind Pharma, Mundipharma, Malesci and Guidotti; c) payment for expert testimony from Chiesi Farmaceutici; d) support for attending meetings and/or travel from the European Respiratory Society; and e) a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid at Elsevier (Deputy Editor of Respiratory Medicine). R. Gosens: his institution has received grants or contracts from Boehringer Ingelheim, Aquilo and Sanofi-Genzyme. N. Hanania: has personally received a) consulting fees as Advisory Committee Member and/or consultant from AstraZeneca, Genentech, GSK, Mylan, Sanofi, Regeneron, Amgen, and Teva (2020–2021); and b) grant/research support from Boehringer Ingelheim, GSK, Novartis, Sanofi Genzyme, Genentech, Mylan (2020–2021). A-H. Maitland-van der Zee: her institution received a) grants or contracts from Health Holland, Amsterdam UMC, Leiden University Medical Center, Maastricht UMC+, Maastricht University, UMC Groningen, UMC Utrecht, Utrecht University, TNO, Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare, Philips, Proefdiervrij, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD, Lung Alliance Netherlands, Lung Foundation Netherlands, Novartis, Vertex, Dutch Lung Foundation grant and Stichting Astma Bestrijding grant; b) consulting fees from AstraZeneca and Boehringer Ingelheim; c) participation on a Data Safety Monitoring Board or Advisory Board as Chair of DSMB SOS BPD study and Advisory board member CHAMP study; and d) leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as President Federation of Innovative Drug Research in the Netherlands and President European Association of systems medicine. P. Rogliani: has personally received consulting fees from Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. M.G. Matera: has personally received a) consulting fees from ABC Farmaceutici, GSK and Chiesi Farmaceutici; and b) payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca and Chiesi Farmaceutici. C.P. Page: has personally received a) grants or contracts from The Defence Science and Technology Laboratory, Goodbody Health, Medical Research Council and Epiendo; b) consulting fees from Epiendo, Recipharm, Glycosinnovation and Eurodrug; c) payment or honoraria from Epiendo, Recipharm, Glycosinnovation and Eurodrug; d) payment for expert testimony from Teva; e) support for attending meetings and/or travel from ERS; f) participation on a Data Safety Monitoring Board or Advisory Board for ACCORD; g) leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as President of the British Pharmacological Society, Trustee of the Fraunhofer Institute of Experimental Medicine and Toxicology, Hanover and UAR Council, non executive director Epiendo and Prep Pharma; and h) stock or stock options in Verona Pharma. D. Singh: has personally received consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance and Verona. D. Stolz: her institution received a) grants or contracts from Swiss National Foundation, Curetis AG, AstraZeneca and Boston Scientifics; and she has personally received b) payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from CSL Behring, Berlin-Chemie Menarini, Novartis, GlaxoSmithKline, AstraZeneca, Curetis AG, Vifor, Merck, Chiesi, Sanofi, MSD and Boehringer Ingelheim; c) participation on a Data Safety Monitoring Board or Advisory Board for GKS and CSL Behring; and d) leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as GOLD representative for Switzerland, Education Council Chair of the European Respiratory Society and President of the Education Committee of the Swiss Respiratory Society. J. Vestbo: has personally received a) consulting fees from ALK Abello, AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Novartis and TEVA; and b) payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer-Ingelheim, Chiesi and GSK.
(Copyright ©ERS 2023.)